Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.

Clinical pharmacology and therapeutics - 1 May 2007

Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson L L, Haefeli W E, Bertilsson L

Abstract excerpt

CYP3A is the main enzyme subfamily involved in the metabolism of the HIV protease-inhibitor saquinavir. We hypothesized that individuals homozygous for CYP3A5*1 might have a higher oral clearance of saquinavir, compared with subjects lacking functional CYP3A5 alleles. A single-dose pharmacokineti...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Cytochrome P-450 CYP3A
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endpoint Determination

Share to HIV Protease Inhibitors

Share to Hydroxylation

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Saquinavir

Source

Identifiers

PMID: 17329995
DOI: 10.1038/sj.clpt.6100117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17329995-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.PMID 17329995Read ↗

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.Semantic proximity Read ↗

Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.Semantic proximity Read ↗

CYP3A5 Genotype Impacts Maraviroc Concentrations in Healthy VolunteersSemantic proximity Read ↗

The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.Semantic proximity Read ↗

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Semantic proximity Read ↗

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.Semantic proximity Read ↗

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.Semantic proximity Read ↗

Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.Semantic proximity Read ↗

Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.Semantic proximity Read ↗

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.